TIDMNCYT
RNS Number : 7022P
Novacyt S.A.
11 October 2023
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
AGM voting
Paris, France, and Eastleigh UK - 11 October 2023 - Novacyt S.A.
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces that shareholders are now able to
vote for the Company's rescheduled Annual General Meeting ("AGM"),
which will be held at 1pm BST/2pm CEST on 26 October 2023 as an
open meeting in Paris. All previous votes remain valid for all
meetings subsequently convened with the same agenda.
As usual, and in accordance with French corporate law, the AGM
comprises both ordinary and extraordinary resolutions. All
materials can be found at www.novacyt.com/investors .
Shareholders wishing to attend the General Meeting in person
may:
- For shareholders whose shares are registered with CIC: present
themselves on the day of the General Meeting, with proof of
identity.
- Shareholders whose shares are registered in bearer form: ask
the authorised intermediary who manages their securities account to
send them a proof of shareholding or a letter of representation,
evidencing that they hold shares of Novacyt.
Shareholders can also request an admission card in advance (a)
from CIC Services, by post to the following address: CIC Services
Assemblées Générales, 6 avenue de Provence 75452 Paris Cedex 09, or
by email to the following address: serviceproxy@cic.fr; or (b) on
the secure VOTACCESS platform accessible via the website
https://www.actionnaire.cic-marketsolutions.eu .
Shareholders are strongly encouraged to submit their votes in
advance, in accordance with the instructions in the Notice of the
AGM.
Shareholders can vote in advance of the AGM by:
-- Downloading a copy of the proxy voting form from the website
www.novacyt.com/investors , completing it and returning it together
with evidence of their shareholding which must be in the form of a
share certificate (attestation) or a letter of representation from
their broker, nominee, bank or authorised intermediary, either by
post to the following address: 6 avenue de Provence 75452 Paris
Cedex 09, or via email to the following address:
serviceproxy@cic.fr , or investor.relations@novacyt.com , no later
than 23 October 2023 inclusive.
-- Voting on-line using the Votaccess portal
http://www.actionnaire.cic-marketsolutions.eu if securities held on
Euronext Growth are registered with any of the following banks:
CIC, Natixis, Société Générale, Caceis, Crédit Agricole, BP2S, BNP
Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital,
Citibank, Deutsche Bank, Bank of New York or JP Morgan. The
Votaccess portal will be open from 11 October 2023 to 25 October
2023 2pm BST/3pm CEST.
-- Voting on-line via a broker, nominee, bank or authorised
intermediary. Many intermediaries in the UK such as Hargreaves
Lansdown are now using the Broadridge ProxyVote on-line voting
portal.
Shareholders can register to view the AGM online by visiting
https://novacytagm23.eventcaster.co.uk , h owever, they will be
unable to vote during the meeting. Registration must be accompanied
by formal evidence of shareholding.
Following the meeting, a recording of the AGM will be available
on the Company's website at www.novacyt.com/investors .
Contacts
Novacyt SA +44 (0)23 8074 8830
James Wakefield, Non-Executive
Chairman
James McCarthy, Acting Chief Executive
Officer
SP Angel Corporate Finance LLP (Nominated
Adviser and Broker) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Numis (Joint Broker) +44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Jack
McLaren
Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780
Stephanie Cuthbert / Anna Dunphy novacyt@walbrookpr.com
/ Phillip Marriage
About Novacyt Group
Novacyt is an international diagnostics business delivering a
broad portfolio of in vitro and molecular diagnostic tests for a
wide range of infectious diseases, enabling faster, more accurate,
accessible testing to improve healthcare outcomes. The Company
provides customers with a seamless sample-to-result workflow using
its integrated and scalable instrumentation/solutions. The Company
specialises in the design, manufacture, and supply of real-time PCR
kits, reagents and a full range of laboratory and qPCR
instrumentation for molecular biology research and clinical use.
Novacyt offers one of the world's most varied and comprehensive
range of qPCR assays, covering human, veterinary, biodefence,
environmental, agriculture and food testing.
The acquisition of Yourgene in September 2023 added a
complementary international genomics technology and services
business, focussed on delivering accurate molecular diagnostic and
screening solutions, across reproductive health and precision
medicine. Yourgene's portfolio of in vitro diagnostic products
includes non-invasive prenatal tests (NIPT) for Down's Syndrome and
other genetic disorders, Cystic Fibrosis screening tests, invasive
rapid aneuploidy tests and DPYD genotyping assays. Yourgene also
works in partnership with global leaders in DNA technology to allow
its Ranger(R) Technology to deliver dynamic target enrichment.
Novacyt is headquartered in Vélizy in France with offices in the
UK in Stokesley, Eastleigh and Manchester. The Company also has
offices in Taipei (divestment pending), Singapore, the US and
Canada and is listed on the London Stock Exchange's AIM market
("NCYT") and on the Paris Stock Exchange Euronext Growth
("ALNOV").
For more information, please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOANKKBQCBDDAKD
(END) Dow Jones Newswires
October 11, 2023 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
